Heidelberg Pharma has filed a patent for humanized and/or deimmunized antibodies that bind to Prostate Specific Membrane Antigen (PSMA) and can be used in the treatment of prostate cancer and other neoplastic and neurological diseases. The patent claim specifies the sequences of the variable heavy and variable light domains of the antibody. GlobalData’s report on Heidelberg Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Heidelberg Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Heidelberg Pharma's grant share as of September 2023 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized antibody for treating prostate cancer and neurological diseases
A recently filed patent (Publication Number: US20230250189A1) describes a humanized antibody or antigen-binding fragment that specifically binds to the extracellular domain of prostate specific membrane antigen (PSMA). The antibody consists of a variable heavy (VH) domain and a variable light (VL) domain, each containing specific sequences known as complementarity-determining regions (CDRs). The patent claims that the antibody does not include a specific combination of CDR sequences.
The patent also claims that the VH domain of the humanized antibody has at least 90% sequence homology to certain specified sequences. Similarly, the VL domain of the antibody has at least 90% sequence homology to other specified sequences.
Furthermore, the patent describes different combinations of VH and VL domain sequences that can be used in the humanized antibody. These combinations involve specific VH domain sequences and a selection of VL domain sequences.
The patent also mentions that the humanized antibody can have different heavy chain and light chain sequences, which are specified in the claims.
The antibody described in the patent is reported to have a high affinity for PSMA, with an EC50 value of less than 0.4 µg/ml.
Additionally, the patent states that the humanized antibody can be glycosylated, with a specific glycan attached to the heavy chain at asparagine 297.
The patent also covers the use of the humanized antibody in various applications, including antibody-drug conjugates (ADCs) and pharmaceutical formulations.
Furthermore, the patent describes a method of treating prostate cancer by administering the humanized antibody to patients suffering from the disease.
The patent also includes claims related to nucleic acids encoding the humanized antibody and host cells capable of producing the antibody.
To know more about GlobalData’s detailed insights on Heidelberg Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
